Pfizer India Launches Two Drugs With Hemas In Sri Lanka
This article was originally published in PharmAsia News
Executive Summary
Pfizer's India arm is launching a pair of drugs in Sri Lanka, one for treating cancer, the other inflammatory disorders, using Hemas Pharmaceuticals as prime distributor. Pfizer India's Managing Director Kewal Handa said the launch is part of the firm's plans to increase its Sri Lanka business, with several more key therapeutic drugs to be launched over the next three years. The two drugs leading the way are Pfizer India's Sutent (sunitinib) for life-threatening cancers and Medrol (methylprednisolone) for use when inflammatory disorders do not respond to conventional drugs satisfactorily. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.